FDA Halts Cellectis Cancer Trials After Patient Dies

Sep 08, 2017

The FDA has ordered Cellectis to shut down two Phase 1 trials for prospective cancer therapy UCART123 after a patient in the studies died nine days after treatment.

Just last week, the FDA approved its first CAR-T therapy, giving Novartis the green light to market Kymriah to treat children and young adults with relapsed acute lymphoblastic leukemia.

Cellectis, a french biopharma company, said a 78-year old man suffering from lymphoma died after experiencing cytokine release syndrome (CRS), a common immune system reaction to CAR-T treatments.

“Cellectis is working closely with the investigators and the FDA in order to resume the trials with an amended protocol including a lowered dosing of UCART123,” said the company in a press release.

Read the press release

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments